Title : Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.

Pub. Date : 2017 May 1

PMID : 27797975






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Background: Ibrutinib is an active therapy with an acceptable safety profile for patients with chronic lymphocytic leukemia (CLL), including high-risk patients with del17p or with TP53 mutations. ibrutinib tumor protein p53 Homo sapiens